Barcelona: What makes a great scientist is not accepting conventional wisdom or dogma but instead thinking differently, pursuing what data generated truly means, and asking if we can do things differently as a result?
Gaudi architecture, Barcelona
Current success in immuno-oncology new product development has been built on basic research done twenty and thirty years ago, when many didn’t believe in leveraging the power of the immune system therapeutically.
At the ongoing European Association for Cancer Research (EACR) “Defense is the Best Attack” meeting in Barcelona this week, many experts in the IO field are sharing novel findings on what may lead to future insights.
What were some of the key take-homes?
Subscribers can read our notes from some of the presentations that stood out at the meeting.
If you’re not yet a BSB subscriber and are interested in learning from our science and clinical commentary/analysis then come join a growing band of enthusiastic readers!
To learn more from our latest conference coverage and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
A warm welcome for Nobel Laureate Dr Jim Allison at CICON18
With all the furore and excitement over Dr Jim Allison’s Nobel prize award that hit CICON18 on Monday, it would be fair to say it was the highlight of the conference for many and it was pretty cool to be there in New York at the time.
Aside from the external news, there were also some intriguing developments to report on the CAR T cell therapy front – you might be forgiven for thinking that there’s not much new to say with two products now approved, but I have to point out that this is a very active area of research and there’s much going on here that is well worth highlighting.
Cell therapy is a bit like the twilight zone in the city that never sleeps – there’s a different vibe and energy about this particular research niche in oncology and quite a few new developments to discuss…
To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.